These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29808997)

  • 1. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
    Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
    Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
    Wu JY; Wang ZX; Zhang G; Lu X; Qiang GH; Hu W; Ji AL; Wu JH; Jiang CP
    Int J Nanomedicine; 2018; 13():1265-1280. PubMed ID: 29551896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
    Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.
    Shi B; Abrams M; Sepp-Lorenzino L
    J Histochem Cytochem; 2013 Dec; 61(12):901-9. PubMed ID: 23979840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
    Wang X; Wu F; Li G; Zhang N; Song X; Zheng Y; Gong C; Han B; He G
    Acta Biomater; 2018 Jul; 74():414-429. PubMed ID: 29787814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
    Han L; Tang C; Yin C
    Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
    Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
    Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer.
    Perrone F; Craparo EF; Cemazar M; Kamensek U; Drago SE; Dapas B; Scaggiante B; Zanconati F; Bonazza D; Grassi M; Truong N; Pozzato G; Farra R; Cavallaro G; Grassi G
    J Control Release; 2021 Feb; 330():1132-1151. PubMed ID: 33212117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
    Zou Y; Guo CG; Yang ZG; Sun JH; Zhang MM; Fu CY
    Drug Des Devel Ther; 2016; 10():1243-55. PubMed ID: 27069355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
    Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
    Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel galactose-PEG-conjugated biodegradable copolymer is an efficient gene delivery vector for immunotherapy of hepatocellular carcinoma.
    Liu L; Zong ZM; Liu Q; Jiang SS; Zhang Q; Cen LQ; Gao J; Gao XG; Huang JD; Liu Y; Yao H
    Biomaterials; 2018 Nov; 184():20-30. PubMed ID: 30195802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells.
    Zhong J; Huang HL; Li J; Qian FC; Li LQ; Niu PP; Dai LC
    Hepatobiliary Pancreat Dis Int; 2015 Feb; 14(1):82-9. PubMed ID: 25655295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.
    Yang Z; Duan J; Wang J; Liu Q; Shang R; Yang X; Lu P; Xia C; Wang L; Dou K
    Int J Nanomedicine; 2018; 13():1851-1865. PubMed ID: 29618926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma.
    Xue WJ; Feng Y; Wang F; Guo YB; Li P; Wang L; Liu YF; Wang ZW; Yang YM; Mao QS
    Sci Rep; 2016 Feb; 6():22149. PubMed ID: 26915683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.
    Sonoke S; Ueda T; Fujiwara K; Kuwabara K; Yano J
    Biol Pharm Bull; 2011; 34(8):1338-42. PubMed ID: 21804229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma.
    Li M; Wang Y; Jiang S; Gao Y; Zhang W; Hu S; Cheng X; Zhang C; Sun P; Ke W; Wang G; Song Z; Zhang Y; Zheng QC
    Nanomedicine (Lond); 2020 Jan; 15(2):145-161. PubMed ID: 31782335
    [No Abstract]   [Full Text] [Related]  

  • 20.
    Sun R; Fang L; Lv X; Fang J; Wang Y; Chen D; Wang L; Chen J; Qi Y; Tang Z; Zhang J; Tian Y
    Drug Deliv; 2021 Dec; 28(1):2071-2084. PubMed ID: 34595970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.